Abstract 16P
Background
NAFLD is a condition commonly found in breast cancer. This study aims at investigating risk factors, and prognostic impact of NAFLD in hormone-positive breast cancer receiving adjuvant hormonal treatment.
Methods
We retrospectively investigated hormone-positive, HER-2-negative, non-metastatic breast cancer patients, diagnosed since January 2010 - December 2018. All patients received hormonal treatment either tamoxifen (Tam), aromatase inhibitor (AI), or tamoxifen followed by aromatase inhibitor (Tam+AI). Clinical data on metabolic profiles (BMI, waist circumference, cholesterol, triglyceride, LDL, HDL, diabetes, or metabolic syndrome [MS]) were collected. Fatty liver displayed by USG. NAFLD diagnosed during hormonal treatment was analyzed based on metabolic risk factors, type of hormonal treatment, and disease-free survival (DFS).
Results
There were 146 eligible patients. MS was detected in 44.5%, and obesity was in 11 % patients. Tam were used in 44.5% patients, whereas Tam+AI in 21.2%, and AI in 34.2%. NAFLD was diagnosed in 31.5% patients. There were significant association between obesity (OR = 3.20; 95%CI 1.12- 9.31; p = 0.024); waist circumference ≥ 80 cm (OR = 7.30; 95%CI 2.43-21.93; p = 0.000); triglyceride ≥ 150 mg/dL (OR = 2.19; 95% CI 1.05-4.56; p = 0.035); HDL ≤ 40 mg/dl (OR = 2.58; 95% CI 1.06-6.32; p = 0.03); MS (OR = 2.65; 95% CI 1.29-5.43; p = 0.007) with arising of NAFLD. Multivariate analysis showed that waist circumference was the strongest predictor to NAFLD (HR 5.92, 95% CI 1.7-19.8; p = 0.004). NAFLD was detected more frequently in tamoxifen-use patients (36.8%) compare to AI (16.6%) (OR = 1.94; 95% CI = 0.90-4.19; p < 0.08). Interestingly, there were less progression events in patients with NAFLD compared to non-NAFLD (23.9% vs. 40%; OR = 0.47, 95% CI 0.2-1.04; p = 0.058). Median survival time was 64 months in non-NAFLD; whereas in NAFLD group the median survival was not reached (HR = 1.813, 95% CI 0.93-3.55; p = 0.08).
Conclusions
Waist circumference predicts NAFLD in breast cancer during adjuvant hormonal therapy. NAFLD patients tend to have longer DFS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
427P - Sahai: A restorative support to address unmet needs of women with cancer – impact on quality of life
Presenter: Poonam Maurya
Session: Poster display session
Resources:
Abstract
428P - A pilot study on comparative efficacy of tramadol or eutectic mixture of local anaesthetics (prilocaine plus lignocaine) in preventing bone marrow aspiration associated pain
Presenter: Bipinesh Sansar
Session: Poster display session
Resources:
Abstract
429P - Skin pathologic change evaluation of the patients who had EGFR inhibitor-related skin adverse events
Presenter: Sung Yong Oh
Session: Poster display session
Resources:
Abstract
430P - Emetic risk of carboplatin plus pemetrexed is higher than that of carboplatin plus paclitaxel in patients with lung cancer: A propensity score-matched analysis
Presenter: Koichi Matsuo
Session: Poster display session
Resources:
Abstract
431P - An in vitro evaluation of CYP2D6 enzymatic inhibition activities of a Chinese herbal medicine formulation (Xiang Bei Yangrong Tang) for the management of cancer-related fatigue
Presenter: Ning Yi Yap
Session: Poster display session
Resources:
Abstract
432P - Chemotherapy induced extravasation: Incidence and possible predictors
Presenter: Shalaka Somayaji
Session: Poster display session
Resources:
Abstract
433P - Prospective outcomes of adolescent and young adult (AYA) patients received treatment from a tertiary cancer hospital in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: Poster display session
Resources:
Abstract
434P - Pneumonitis induced antineoplastic agents: Mortality and risk factors in 129 consecutive cases
Presenter: Sawako Kaku
Session: Poster display session
Resources:
Abstract
435P - Telephonic communication in palliative care for better management of terminal cancer patients in rural India: An NGO based approach
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
436P - Assessing the quality of life of Filipino cancer patients: A survey of Filipino oncologists
Presenter: Frederic Ivan Ting
Session: Poster display session
Resources:
Abstract